Navigation Links
Agendia Appoints New Chief Financial Officer
Date:1/8/2009

HUNTINGTON BEACH, California, and AMSTERDAM, January 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Kurt Schmidt, CPA, MBA, as the company's new Chief Financial Officer.

"Kurt is an exceptional addition to our team and an invaluable asset," said Bernhard Sixt, Ph.D., President and Chief Executive Officer. "With his extensive financial management experience in the high tech and healthcare industries, he will be instrumental in driving Agendia's next phase of growth."

Mr. Schmidt succeeds former Chief Financial Officer, John de Die, who has been an exemplary guide for Agendia during his tenure. Mr. Schmidt brings more than 25 years of financial, operational and entrepreneurial management experience, primarily in the high tech and healthcare industries in the U.S. and Europe. Most recently, he was a principal at a consulting firm he founded in 2002, providing high-level interim financial management and M&A services. Prior to that, Mr. Schmidt served as Operations Director at B2eMarkets, a supply chain technology company, and Director of Finance & Operations at LA Gear Europe. Mr. Schmidt started his career at Cardinal Health, Inc. in corporate finance.

"I am delighted to join Agendia during this exciting time and help prepare the company for our next financing round. I look forward to our first investor meetings next week during the JP Morgan Healthcare Conference in San Francisco," commented Kurt Schmidt, Chief Financial Officer.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
2. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
3. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
4. Agendia BV Appoints Clinical and Scientific Advisory Board
5. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
6. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
7. Agendia Joins the Personalized Medicine Coalition (PMC)
8. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
9. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
10. Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer
11. Algeta Appoints Andrew Kay as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... time members of the Modular Building Institute (MBI), an international modular trade organization, ... the permanent modular category for the Pagliuca Life Lab at Harvard University. The ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... YORK , March 28, 2017 ... highly volatile and unpredictable sector due to the ... Markets served include medical, agricultural, environmental, and industrial. In ... four stocks: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), OvaScience ... and Ocular Therapeutix Inc. (NASDAQ: OCUL ...
(Date:3/27/2017)... WARREN, N.J. , March 27, 2017 Roka ... providing advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Spring 2017 Convention on March ... the New York Marriott Marquis. About Roka ... ...
Breaking Biology Technology:
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):